Dupilumab Provided Less Relief for Young Children
A study found children under six reported lower quality-of-life improvements than older patients during eczema treatment.
Updated on Sept. 28, 2026 in Allergies
Live Poll
Do you trust that new medical treatments for children are equally effective across all age groups?
A longitudinal study of 309 patients found that while dupilumab significantly reduced eczema severity, children younger than 6 reported lower quality-of-life benefits than older groups. Researchers noted that younger children also experienced higher rates of treatment discontinuation.
Why it matters
The findings highlight distinct challenges in treating atopic dermatitis in young children, who may struggle more with the physical demands of injection therapy. Understanding these variations helps clinicians better tailor care strategies to patient age.
The study tracked 309 participants, showing an eczema severity drop from 16.3 to 3.4 over three years. While effective, 63.1% of patients experienced at least one adverse effect, and over one third developed dupilumab-associated ocular surface disease.
The players
Food and Drug Administration
The federal agency is responsible for protecting public health by ensuring the safety and efficacy of human drugs and biological products.
American Academy of Dermatology
This professional organization represents dermatologists and sets clinical practice standards for skin disease management.
The details
Patients underwent injections in the thigh, abdomen, or upper arm every 2 to 4 weeks, with caregivers and patients self-reporting on pruritus and quality of life. Younger children reported a quality-of-life score of 7.2, significantly higher than the 2.7 score recorded by teens.
Timeline
The clinical cohort study was conducted in the Netherlands between 2019 and 2025.
The FDA approved the use of dupilumab for children younger than 5 in 2022.
The American Academy of Dermatology issued relevant treatment guidelines in early 2026.
Health Landscape
This research follows the 2022 FDA approval of dupilumab for children younger than 5, providing critical long-term performance metrics for the therapy. It marks a transition from initial clinical safety trials to assessing how different age groups navigate the burdens of chronic care.
Parents should be aware that children under 6 may face greater difficulty with injection administration, which can impact consistent treatment adherence. Clinicians and families can use these findings to discuss potential alternative support strategies for younger patients.
The takeaway
Treatment success in pediatric dermatology often requires balancing physiological efficacy with the practical realities of a child's developmental stage. Caregivers may benefit from focused training on injection techniques to mitigate the higher discontinuation rates seen in younger populations.
Further reading
For more information on managing skin conditions, visit the Allergies section.
Source note: This article includes information reported by Medscape.
Live Poll
Do you trust that new medical treatments for children are equally effective across all age groups?
